

## Citi Pharma Limited

October 30, 2023

The General Manager Pakistan Stock Exchange Limited Stock Exchange Building Stock Exchange Road Karachi.

Financial results for the 1st quarter ended September 30, 2023

Dear Sir,

We have to inform you that the Board of Directors of the company in their meeting held on October 27, 2023 at Lahore have approved the financial statements for the 1st Quarter ended on September 30, 2023 and recommended the following.

Cash Dividend	Nil
Bonus Shares	Nil
Right Shares	Nil
Any other entitlement/corporate action	Nil
Any other Price sensitive information	Nil

## Financial Performance:

While reviewing the Company financial performance for the quarter ended, the Board appreciated the efforts of the management in the area of operation and posting the financial results.

Financial results of the company for the first quarter ended September 30, 2023 are enclosed.

Quarterly report of the Company for the quarter ended September 30, 2023 will be transmitted through PUCARS separately, within the specified time.

Yours Sincerely,

Rizwan Ahmad **Chief Executive Officer** 



Executive Director/HOD, Offsite-II, Department

Supervision Division, Securities & Exchange Commission of Pakistan



588 - Q, Johar Town, Lahore - Pakisatn



3KM. Head Balloki Road, Phool Nagar, District Kasur - Pakistan



Head Office: +92. 42. 35316587 - 90 | Factory: +92. 49. 4510189, +92. 49. 4513392 www.citipharma.com.pk







## Citi Pharma Limited

CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS (UN-AUDITED)

	Quarter	Quarter Ended	
	September 30, 2023 (Un-audited)	September 30, 2022 (Un-audited)	
Sales-Net	2,701,228,267	3,118,074,356	
Cost of sales	(2,454,760,271)	(2,747,684,203)	
Gross profit	246,467,996	370,390,153	
Administrative expenses	48,262,551	49,715,005	
Selling and Distribution expenses	38,634,053	37,663,377	
Sching and Distriction expenses	(86,896,605)	(87,378,383)	
Operating Profit	159,571,391	283,011,771	
Financial Charges	(86,808,489)	(157,053,888)	
The local County	72,762,902	125,957,882	
Other income/(Loss)	106,208,183	47,598,134	
	178,971,084	173,556,016	
Other Expenses	(12,344,735)	(4,219,670)	
Profit before Taxation	166,626,349	169,336,346	
Taxation	(72,174,810)	(23,527,710)	
Profit for the period	94,451,539	145,808,636	
Earnings per share (EPS) - Basic and Diluted	0.41	0.64	
101			















